Is BLCO or NEOG more profitable?

Neogen has a net margin of -0.91% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -3.21% 4.14% 1.93% Neogen -0.91% 2.78% 1.74%

Does the media favor BLCO or NEOG?

In the previous week, Neogen had 12 more articles in the media than Bausch + Lomb. MarketBeat recorded 25 mentions for Neogen and 13 mentions for Bausch + Lomb. Neogen's average media sentiment score of 1.13 beat Bausch + Lomb's score of 0.31 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Neogen 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NEOG or MMSI?

In the previous week, Neogen had 1 more articles in the media than Merit Medical Systems. MarketBeat recorded 25 mentions for Neogen and 24 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.26 beat Neogen's score of 1.13 indicating that Merit Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merit Medical Systems 11 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ICUI or NEOG?

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ICU Medical $2.23B 1.96 $730K $1.18 148.39 Neogen $870.40M 2.92 -$7.90M -$0.03 N/A

Is ICUI or NEOG more profitable?

ICU Medical has a net margin of 1.39% compared to Neogen's net margin of -0.91%. ICU Medical's return on equity of 7.91% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets ICU Medical 1.39% 7.91% 4.17% Neogen -0.91% 2.78% 1.74%

Does the media refer more to ICUI or NEOG?

In the previous week, Neogen had 15 more articles in the media than ICU Medical. MarketBeat recorded 25 mentions for Neogen and 10 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.37 beat Neogen's score of 1.13 indicating that ICU Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ICU Medical 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NEOG or NVST?

Envista has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neogen $870.40M 2.92 -$7.90M -$0.03 N/A Envista $2.72B 1.60 $47M $0.58 46.81

Is NEOG or NVST more profitable?

Envista has a net margin of 3.33% compared to Neogen's net margin of -0.91%. Envista's return on equity of 7.88% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Neogen -0.91% 2.78% 1.74% Envista 3.33% 7.88% 4.33%

Does the media refer more to NEOG or NVST?

In the previous week, Neogen had 13 more articles in the media than Envista. MarketBeat recorded 25 mentions for Neogen and 12 mentions for Envista. Neogen's average media sentiment score of 1.13 beat Envista's score of 1.04 indicating that Neogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Envista 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend UFPT or NEOG?

Neogen has a consensus target price of $12.00, suggesting a potential upside of 2.92%. Given Neogen's stronger consensus rating and higher probable upside, analysts plainly believe Neogen is more favorable than UFP Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UFP Technologies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Neogen 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is UFPT or NEOG more profitable?

UFP Technologies has a net margin of 11.45% compared to Neogen's net margin of -0.91%. UFP Technologies' return on equity of 18.42% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets UFP Technologies 11.45% 18.42% 11.96% Neogen -0.91% 2.78% 1.74%

Does the media favor UFPT or NEOG?

In the previous week, Neogen had 9 more articles in the media than UFP Technologies. MarketBeat recorded 25 mentions for Neogen and 16 mentions for UFP Technologies. UFP Technologies' average media sentiment score of 1.21 beat Neogen's score of 1.13 indicating that UFP Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UFP Technologies 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neogen (NEOG) Competitors

$11.66 -0.08 (-0.68%)

As of 08/28/2026 04:00 PM Eastern

Compare

NEOG vs. BLCO, MMSI, ICUI, NVST, and UFPT

Should you buy Neogen stock or one of its competitors? Neogen's main competitors and comparable companies include Bausch + Lomb (BLCO), Merit Medical Systems (MMSI), ICU Medical (ICUI), Envista (NVST), and UFP Technologies (UFPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Neogen compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Neogen has lower revenue, but higher earnings than Bausch + Lomb. Neogen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.20	-$360M	-$0.48	N/A
Neogen	$870.40M	2.92	-$7.90M	-$0.03	N/A

In the previous week, Neogen had 12 more articles in the media than Bausch + Lomb. MarketBeat recorded 25 mentions for Neogen and 13 mentions for Bausch + Lomb. Neogen's average media sentiment score of 1.13 beat Bausch + Lomb's score of 0.31 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Neogen	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bausch + Lomb has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Neogen has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Neogen has a net margin of -0.91% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Neogen	-0.91%	2.78%	1.74%

Bausch + Lomb currently has a consensus price target of $18.75, indicating a potential upside of 9.46%. Neogen has a consensus price target of $12.00, indicating a potential upside of 2.92%. Given Bausch + Lomb's higher probable upside, research analysts plainly believe Bausch + Lomb is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Neogen beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

How does Neogen compare to Merit Medical Systems?

Neogen (NASDAQ:NEOG) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

In the previous week, Neogen had 1 more articles in the media than Merit Medical Systems. MarketBeat recorded 25 mentions for Neogen and 24 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.26 beat Neogen's score of 1.13 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merit Medical Systems	11 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Merit Medical Systems has a net margin of 9.22% compared to Neogen's net margin of -0.91%. Merit Medical Systems' return on equity of 13.75% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
Merit Medical Systems	9.22%	13.75%	8.10%

Neogen presently has a consensus price target of $12.00, indicating a potential upside of 2.92%. Merit Medical Systems has a consensus price target of $100.00, indicating a potential upside of 10.51%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, analysts plainly believe Merit Medical Systems is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Neogen has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Merit Medical Systems has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	2.92	-$7.90M	-$0.03	N/A
Merit Medical Systems	$1.52B	3.56	$128.49M	$2.42	37.39

Summary

Merit Medical Systems beats Neogen on 15 of the 17 factors compared between the two stocks.

How does Neogen compare to ICU Medical?

ICU Medical (NASDAQ:ICUI) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

ICU Medical has a net margin of 1.39% compared to Neogen's net margin of -0.91%. ICU Medical's return on equity of 7.91% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICU Medical	1.39%	7.91%	4.17%
Neogen	-0.91%	2.78%	1.74%

ICU Medical presently has a consensus price target of $192.80, indicating a potential upside of 10.11%. Neogen has a consensus price target of $12.00, indicating a potential upside of 2.92%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICU Medical	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.89
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICU Medical	$2.23B	1.96	$730K	$1.18	148.39
Neogen	$870.40M	2.92	-$7.90M	-$0.03	N/A

In the previous week, Neogen had 15 more articles in the media than ICU Medical. MarketBeat recorded 25 mentions for Neogen and 10 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.37 beat Neogen's score of 1.13 indicating that ICU Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ICU Medical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.1% of ICU Medical shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 2.1% of ICU Medical shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ICU Medical has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Neogen has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

ICU Medical beats Neogen on 13 of the 17 factors compared between the two stocks.

How does Neogen compare to Envista?

Neogen (NASDAQ:NEOG) and Envista (NYSE:NVST) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

96.7% of Neogen shares are held by institutional investors. 0.6% of Neogen shares are held by company insiders. Comparatively, 1.0% of Envista shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neogen had 13 more articles in the media than Envista. MarketBeat recorded 25 mentions for Neogen and 12 mentions for Envista. Neogen's average media sentiment score of 1.13 beat Envista's score of 1.04 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envista	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envista has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	2.92	-$7.90M	-$0.03	N/A
Envista	$2.72B	1.60	$47M	$0.58	46.81

Neogen currently has a consensus target price of $12.00, suggesting a potential upside of 2.92%. Envista has a consensus target price of $29.31, suggesting a potential upside of 7.95%. Given Envista's stronger consensus rating and higher probable upside, analysts clearly believe Envista is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50

Envista has a net margin of 3.33% compared to Neogen's net margin of -0.91%. Envista's return on equity of 7.88% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
Envista	3.33%	7.88%	4.33%

Neogen has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Envista has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Envista beats Neogen on 12 of the 17 factors compared between the two stocks.

How does Neogen compare to UFP Technologies?

UFP Technologies (NASDAQ:UFPT) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

UFP Technologies has higher earnings, but lower revenue than Neogen. Neogen is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UFP Technologies	$602.80M	3.86	$68.31M	$9.28	32.33
Neogen	$870.40M	2.92	-$7.90M	-$0.03	N/A

In the previous week, Neogen had 9 more articles in the media than UFP Technologies. MarketBeat recorded 25 mentions for Neogen and 16 mentions for UFP Technologies. UFP Technologies' average media sentiment score of 1.21 beat Neogen's score of 1.13 indicating that UFP Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
UFP Technologies	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

UFP Technologies has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Neogen has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Neogen has a consensus target price of $12.00, suggesting a potential upside of 2.92%. Given Neogen's stronger consensus rating and higher probable upside, analysts plainly believe Neogen is more favorable than UFP Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UFP Technologies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

87.3% of UFP Technologies shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 4.6% of UFP Technologies shares are owned by insiders. Comparatively, 0.6% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

UFP Technologies has a net margin of 11.45% compared to Neogen's net margin of -0.91%. UFP Technologies' return on equity of 18.42% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UFP Technologies	11.45%	18.42%	11.96%
Neogen	-0.91%	2.78%	1.74%

Summary

UFP Technologies beats Neogen on 9 of the 16 factors compared between the two stocks.

Get Neogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEOG vs. The Competition

Export

Metric	Neogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.54B	$5.88B	$7.21B	$12.91B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-388.67	25.92	273.16	25.42
Price / Sales	2.92	67.85	615.35	86.95
Price / Cash	13.83	33.03	76.74	53.00
Price / Book	1.21	6.18	12.98	6.14
Net Income	-$7.90M	$149.01M	$3.48B	$348.86M
7 Day Performance	-2.43%	-0.24%	0.13%	-0.80%
1 Month Performance	1.13%	6.18%	7.08%	4.13%
1 Year Performance	102.78%	6.30%	24.67%	15.17%

Neogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEOG Neogen	2.2869 of 5 stars	$11.66 -0.7%	$12.00 +2.9%	+102.8%	$2.54B	$870.40M	N/A	2,110	News Coverage Positive News Analyst Upgrade Analyst Revision
BLCO Bausch + Lomb	3.1529 of 5 stars	$17.34 +0.6%	$18.75 +8.2%	+17.1%	$6.16B	$5.10B	N/A	13,000	Analyst Forecast
MMSI Merit Medical Systems	3.874 of 5 stars	$90.28 -0.6%	$100.00 +10.8%	-0.1%	$5.42B	$1.52B	37.31	7,500	Positive News Analyst Upgrade Analyst Revision
ICUI ICU Medical	3.4846 of 5 stars	$182.55 -0.2%	$192.80 +5.6%	+37.2%	$4.57B	$2.16B	154.70	13,000
NVST Envista	2.9883 of 5 stars	$27.34 +0.5%	$29.31 +7.2%	+28.4%	$4.37B	$2.72B	47.15	12,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEOG) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neogen (NEOG) Competitors

NEOG vs. BLCO, MMSI, ICUI, NVST, and UFPT

How does Neogen compare to Bausch + Lomb?

Summary

How does Neogen compare to Merit Medical Systems?

Summary

How does Neogen compare to ICU Medical?

Summary

How does Neogen compare to Envista?

Summary

How does Neogen compare to UFP Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neogen (NEOG) Competitors

NEOG vs. BLCO, MMSI, ICUI, NVST, and UFPT

How does Neogen compare to Bausch + Lomb?

Which has stronger valuation and earnings, BLCO or NEOG?

Does the media favor BLCO or NEOG?

Do insiders & institutionals believe in BLCO or NEOG?

Which has more volatility and risk, BLCO or NEOG?

Is BLCO or NEOG more profitable?

Do analysts recommend BLCO or NEOG?

Summary

How does Neogen compare to Merit Medical Systems?

Does the media refer more to NEOG or MMSI?

Is NEOG or MMSI more profitable?

Do analysts rate NEOG or MMSI?

Which has more risk & volatility, NEOG or MMSI?

Do institutionals & insiders believe in NEOG or MMSI?

Which has preferable earnings & valuation, NEOG or MMSI?

Summary

How does Neogen compare to ICU Medical?

Is ICUI or NEOG more profitable?

Do analysts recommend ICUI or NEOG?

Which has preferable valuation & earnings, ICUI or NEOG?

Does the media refer more to ICUI or NEOG?

Do institutionals & insiders believe in ICUI or NEOG?

Which has more volatility and risk, ICUI or NEOG?

Summary

How does Neogen compare to Envista?

Do insiders and institutionals have more ownership in NEOG or NVST?

Does the media refer more to NEOG or NVST?

Which has stronger valuation & earnings, NEOG or NVST?

Do analysts recommend NEOG or NVST?

Is NEOG or NVST more profitable?

Which has more volatility & risk, NEOG or NVST?

Summary

How does Neogen compare to UFP Technologies?

Which has stronger earnings & valuation, UFPT or NEOG?

Does the media favor UFPT or NEOG?

Which has more volatility and risk, UFPT or NEOG?

Do analysts recommend UFPT or NEOG?

Do insiders & institutionals hold more shares of UFPT or NEOG?

Is UFPT or NEOG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools